• 1.jpg
  • 2.jpg
  • 4.jpg
  • 5.jpg
  • 6.jpg
  • 7.jpg
  • DSCF6103.jpg
  • DSCF6330.jpg
  • DSCF6361.jpg
  • DSCF6682.jpg
  • DSCF7352.jpg
  • DSCF7463.jpg
  • DSCF7655.jpg
  • DSCF7700.jpg
  • DSCF7758.jpg
  • DSCF7761.jpg
  • 8.jpg
  • 9.jpg

Registration online for the Summit is possible until June 23 Midnight. After that you may also register on Site at the Registration Desk.

During the exhibition, you can test your samples on the STED Microscope. The requirements how samples must be prepared is written in the labelling protocols, which you can download here

clinam-9-2016

Conference and Exhibition

European & Global Summit for Cutting-Edge Medicine

June 26 – 29, 2016

Clinical Nanomedicine and Targeted Medicine

Enabling Technologies for Personalized Medicine

FINAL PROGRAMME (19.6.16)
Registration Desk at Center:
Sunday 16.00 - 18.00; Monday, Tuesday 07.30 - 18.00; Wednesday 07.30 - 16.00

 

colab4

 

Conference Venue:
Congress Center, Messeplatz 21, 4058 Basel, Switzerland
Phone + 41 58 206 28 28  This email address is being protected from spambots. You need JavaScript enabled to view it.
Organizers Office:
European Foundation for Clinical Nanomedicine (CLINAM)
Alemannengasse 12, P.B. 4016 Basel, Switzerland
Phone +41 61 695 93 95  clinam@clinam.org
Registration Office:
Organizers Schweiz GmbH, CLINAM SUMMIT 9/2016
Obere Egg 2, CH 4312 Magden, Switzerland
Phone +41 61 836 98 78  This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Congress Center Basel, Messeplatz 21, 2058 Basel 2nd Floor, Switzerland, Phone +41 58 206 28


The Collaborators of the European and Global CLINAM-Summit 2016

• Federal Department of Economic Affairs, Education and Research of the Swiss Confederation, Bern (CH) • Association for Cancer Immunotherapy (CIMT). Mainz (D) • BioNanoNet Forschungs‐GmbH, Graz (A) • Cantons of Basel (CH) • Chinese Academy of Sciences, Beijing (RC) • De Gruyter – European Journal of Nanomedicine, Berlin (D) • DIA Europe, Middle East & Africa, Basel (CH) • EMPA, Swiss Federal Laboratories for Materials Science, Dübendorf (CH) • European Academy of Sciences and Arts, Salzburg (A) • European Commission, Brussels (B) • European Forum for Good Clinical Practice EFGCP), Brussels (B) • European Materials Research Society, Strasbourg (F) • European Medicines Agency (EMA), London (UK) • European Society for Nanomedicine, Basel (CH) • European Technology Platform of Nanomedicine (ETPN) • Euro Nanotox Letters (A) • Freiwillige Akademische Gesellschaft (FAG, Basel) (CH) • Food and Drug Administration, (FDA) Silver Spring (USA) • Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Saarbrücken (D) • Innovative Medicines Initiative, (IMI) Brussels • International Association for Pharmaceutical Technology (APV), Mainz (D) • Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Beijing (RC) • Lundbeckfonden Center of Excellence NanoCAN, Odense (DK) • Nanomedicines Alliances, Research Triangle Park (USA) • National Institute of Health Sciences of Japan, Tokyo (J) • National Center for Nanoscience and Technology of China, Beijing (RC) • Non Biological Complex Drugs Working Group, (NBCD) Leiden(NL) • Nanotech Characterization Laboratory, National Cancer Institute, Frederick (USA) • Swiss Biotech Association, Zürich (CH) • University of Basel, Basel (CH)

The Sponsors of the European and Global CLINAM-Summit 2016

• Federal Department of Economic Affairs, Education and Research of the Swiss Confederation, Bern (CH) • Actelion Pharmaceuticals Ltd. Allschwil (CH) • Freiwillige Akademische Gesellschaft Basel, • The Canton of Basel‐ Stadt(CH) • The Canton of Basel‐Land (CH) • Clariant International AG, Pratteln (CH) • Isaac Dreyfus Bernheim Foundation, Basel (CH) • European Materials Forum, Brussels (B) • European Materials Research Society (E‐MRS), Strasbourg (F) • GAG AG, Basel (CH) • Löffler & Associates GmbH ‐ Concept Engineering, Basel (CH) • Lonza Ltd., Basel (CH) • Novartis (CH) • Roche (CH) • Swiss NanoScience Institute, Basel • Swiss National Science Foundation, Bern (CH) • Tarveda Therapeutics, Watertown, MA (USA) • TecoMedical Group, Sissach (CH) • University of Basel (CH)

Scientific Committee

• Prof. Dr. med. Patrick Hunziker, University Hospital Basel (CH) (chairman) • Prof. Dr. med. Christoph Alexiou, University Hospital Erlangen (D) • Prof. Dr. Lajos Balogh, AA Nanomedicine and Nanotechnology Consultants, North Andover, Massachusetts, American Society for Nanomedicine, Boston (USA) • Prof. Dr. Gerd Binnig, Nobel Laureate, Munich (D) • Prof. Dr. Yechezkel Barenholz, Hebrew University, Hadassah Medical School, Jerusalem (IL) • Prof. Dr. med. Omid Farokhzad, Associate Professor and Director of Laboratory of Nanomedicine and Biomaterials, Harvard Medical School and Brigham and Women's Hospital, (USA) • Prof. Dr. med. Dong Soo Lee, PhD. Chairman Department of Nuclear Medicine Seoul National University Seoul (KOR) • Dr. med. h.c. Beat Löffler, MA CLINAMFoundation, Basel (CH) • Prof. Dr. Jan Mollenhauer, Lundbeckfonden Center of Excellence NanoCAN, Odense (DK) • Prof. Dr. med. Marisa Papaluca Amati, European Medicines Agency, London (UK) •Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Utrecht University, (NL) • Prof. Dr. Viola Vogel, Laboratory for Biologically Oriented Materials, ETH, Zürich (CH)

Introduction – The Conference at a Glance

In the previous eight years, the CLINAM Summit grew to the largest in its field with 12 presenting Noble Laureates and more than 500 participants from academia, industry, regulatory authorities and policy from over 40 countries in Europe and worldwide. With this success and broad support by well 31 renowned collaborating initiatives, the CLINAM‐Summit is today a most important marketplace for scientific exchange and discussions of clinical, regulatory, political and ethical aspects in this field of cutting‐edge medicine. The CLINAM Summit emerged as exquisite forum for translation from bench to bedside for European and international networking, for industrial collaboration between companies, with academia, and as point‐of‐contact with customers. The summit is presently the only place to meet every year the regulatory authorities from all continents to debate the needs of all stakeholders in the field. CLINAM 9/2016 continues with its tradition to cover the manifold interdisciplinary fields of Clinical and Targeted Nanomedicine in major and neglected diseases. As special focus area, CLINAM 09/2016 adds translation and enabling technologies, including, cutting‐edge molecular profiling, nano‐scale analytics, single cell analysis, stem cell technologies, tissue engineering, in and ex vivo systems as well as in vitro substitute systems for efficacy and toxicity testing. CLINAM 09/2016 covers the spectrum of Nanomedicine and Targeted Medicine from new materials and enabling technologies over diagnostic and therapeutic translation to clinical applications in infectious, inflammatory and neurodegenerative diseases, cancer and regenerative medicine to societal implications, strategical issues, and regulatory affairs. The Summit is divided into four tracks in parallel and provides ample possibilities for exhibitors to make decision maker contacts. The Nobel Laureate Prof. Stefan Hell will open the Summit. Participants are invited to bring samples to test the Stimulated Emission Depletion (STED) Microscopy within the exhibition. Live Testing the STED Microscope The presence of a STED Microscope will give for participants of CLINAM the possibility to bring samples and to investigate the revolutionary visibility. All participants get a link for label protocols before the Summit which gives information how to prepare the samples. STED Microscopes are currently in the market by the companies Abberior and Leica. The initiative to enable people to investigate comes from CLINAM in cooperation with Beckman Coulter, Leica and Abberior.

Exhibitors 2016

exhibitors6

Exhibiting Universities 2016


Switzerland (Basel) • Italy (Milan) • Denmark (Odense) • Israel (Tel Aviv)

The Netherlands (Twente) • Hungary (Budapest) • Norway (Trondheim)

 

The Sponsors




 The Foundation

The European Foundation for Clinical Nanomedicine is a non-profit institution aiming at advancing medicine to the benefit of individuals and society through the application of nanoscience. Aiming at prevention, diagnosis, and therapy through nanomedicine as well as at exploration of its implications, the Foundation reaches its goals through support of clinically focussed research and of interaction and information flow between clinicians, researchers, the public, and other stakeholders. The recognition of the large future impact of nanoscience on medicine and the observed rapid advance of medical applications of nanoscience have been the main reasons for the creation of the Foundation.

Nanotechnology for Medicine

Nanotechnology is generally considered as the key technology of the 21st century. It is an interdisciplinary scientific field focusing on methods, materials, and tools on the nanometer scale, i.e. one millionth of a millimeter. The application of this science to medicine seeks to benefit patients by providing prevention, early diagnosis, and effective treatment for prevalent, for disabling, and for currently incurable medical conditions.